Herceptin (trastuzumab) / Roche - LARVOL DELTA

A DESTINY-Breast09 (DB-)09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs) (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer (SABCS 2025) - P3 | "In the HER2CLIMB-05 trial, the addition of tucatinib to TRAS + PERT as 1L maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in PFS with a manageable safety profile in patients with HER2+ MBC."

Clinical • Combination therapy • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • HER-2

Can Biomarker-Based Monitoring Detect the Early Development of Diastolic Dysfunction During Chemotherapy? (PubMed, Medicina (Kaunas)) - "All patients received an anthracycline-based chemotherapy regimen, cyclophosphamide, docetaxel and trastuzumab. The regression analyses suggest that this phenotype is multifactorial, with echocardiographic indices capturing the functional component and circulating biomarkers reflecting complementary aspects of the underlying biological response. This multimodal approach may therefore help identify patients with early treatment-related cardiac changes and potentially those at increased risk of subsequent CTRCD, particularly during a period when conventional LVEF-based surveillance may still appear reassuring."

Biomarker • Journal • Observational data • Breast Cancer • Cardiovascular • Congestive Heart Failure • Heart Failure • Oncology • Solid Tumor • GDF15 • LGALS3 • TNNI3

Cardioprotective Potential of Grape-Derived Polyphenols in Cancer Therapy-Related Cardiotoxicity. (PubMed, Int J Mol Sci) - "The purpose of this review is to highlight the development of cardiotoxicity associated with the use of anthracyclines or trastuzumab and to examine prevention and treatment methods using polyphenols, biologically active substances that hold significant therapeutic potential. The main mechanisms of this pathology, modern biomarkers for detection, and the classification and biological activity of polyphenols are discussed. Emphasis is placed on polyphenols found in grapes and their antioxidant potential as a protector of the cardiovascular system."

Journal • Review • Breast Cancer • Cardiovascular • Oncology • Solid Tumor

Reassessing the Role of Anthracyclines in Early HER2-Positive Breast Cancer in the Era of HER2-Targeted Therapy and Treatment De-Escalation: A Systematic Review and Narrative Synthesis. (PubMed, J Clin Med) - "The available evidence supports selective rather than routine anthracycline use, with treatment decisions guided by the anticipated oncologic benefit, cardiovascular risk, tumor characteristics, treatment setting, and patient preferences. Registration: PROSPERO CRD420261296599; registered on 29 January 2026."

Journal • Review • Breast Cancer • Cardiovascular • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

A case report on the management of sepsis complicated by eroded mixed hemorrhoids following breast cancer chemotherapy. (PubMed, Medicine (Baltimore)) - "This case demonstrates that in severely neutropenic and thrombocytopenic patients, a conservative, integrated approach combining systemic anti-infective therapy with advanced local wound care and traditional Chinese medicine can successfully manage life-threatening sepsis originating from eroded hemorrhoids. It underscores the critical importance of perianal hygiene, prompt management of chemotherapy-induced constipation and bone marrow suppression, and the potential of nonsurgical strategies in high-risk surgical candidates."

Journal • Breast Cancer • Chemotherapy-Induced Neutropenia • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • HER2 Positive Breast Cancer • Infectious Disease • Neutropenia • Oncology • Septic Shock • Solid Tumor • Thrombocytopenia • HER-2

A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancer (clinicaltrials.gov) - P2 | N=30 | Enrolling by invitation | Sponsor: Saitama Breast Cancer Clinical Study Group | Unknown status ➔ Enrolling by invitation

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A phase II clinical trial (KSCC/HGCSG/CCOG/PerSeUS1501B) examining oxaliplatin + S-1 + trastuzumab for treatment of HER2-positive advanced/recurrent gastric cancer previously untreated with chemotherapy (clinicaltrials.gov) - P2 | N=40 | Completed | Sponsor: Kyushu Study group of Clinical Cancer | Unknown status ➔ Completed

Trial completion • Gastric Cancer • Oncology • Solid Tumor • HER-2

Trastuzumab incombination with S-1/CDDP of HER2-positive advanced gastric cancer: a phase II trial. (clinicaltrials.gov) - P=N/A | N=30 | Completed | Sponsor: Dept. of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences; Nagoya Daini Red Cross Hospital, Nagoya City Eas | Unknown status ➔ Completed

Trial completion • Gastric Cancer • Oncology • Solid Tumor • HER-2

Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer. (clinicaltrials.gov) - P2 | N=35 | Enrolling by invitation | Sponsor: Sairtama Breast Cancer Clinical Study Group (SBCCSG)na | Unknown status ➔ Enrolling by invitation

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Feasibility and safety of 30-minute Trastuzumab reloading infusion in patients with HER2-positive solid tumors. (PubMed, J Oncol Pharm Pract) - "The IRR rate was 0% in 30 min vs. 4% in 90 min. Additionally, the mean percentage of LVEF reduction was similar between the two cohorts (4.1% in 30 min vs. 3.97% in 90 min; P = 0.99).ConclusionsTrastuzumab reloading doses can be safely administered as a 30-min infusion, without increased risk of IRR or cardiotoxicity."

Journal • Breast Cancer • Cardiovascular • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Identification of key genes and pathways involved in trastuzumab resistance in HER2-positive gastric cancer through integrative bioinformatics analysis. (PubMed, Iran J Basic Med Sci) - "Trastuzumab resistance may involve networks related to transcriptional plasticity, adhesion dynamics, and RTK redundancy. This study provides a hypothesis-generating framework for future biomarker-guided combination strategies, which requires validation in HER2-positive cohorts and experimental models."

Journal • Gastric Cancer • Oncology • Solid Tumor • CDH2 • HER-2 • VIM

Pure Red Cell Aplasia Following Neoadjuvant Docetaxel/Carboplatin/Trastuzumab (TCbH) in a 45‑Year‑Old Woman With Breast Cancer Successfully Treated With Cyclosporine. (PubMed, Am J Case Rep) - "During the adjuvant trastuzumab/pertuzumab (HP) treatment, Hb remained ≥110 g/L. In this patient, cyclosporine was effective; after anemia correction, HP was tolerated. The observed gBRCA1 mutation is a hypothesis-generating finding requiring further validation."

Journal • Aplastic Anemia • Breast Cancer • Hematological Disorders • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Immunology • Infectious Disease • Oncology • Solid Tumor • Thymoma • Thymus Cancer • BRCA1 • HER-2

GLP-1 Receptor Agonist Reduces Anthracycline and Trastuzumab–Induced Cardiac Dysfunction and Systemic hs-CRP, IL-1β and IL-6 in Non-Diabetic Preclinical Models of Cardio-Oncology (ESMO 2026) - No abstract available

Preclinical • Oncology • IL1B • IL6

Socioeconomic and organizational impacts of subcutaneous fixed-dose combination (PH FDC SC) vs intravenous (P+H IV) pertuzumab and trastuzumab in HER2-positive breast cancer (BC): PHOCUS study in Korea (ESMO 2026) - No abstract available

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Prognostic Factors and Survival Outcomes in HER2-Positive Metastatic Gastric/GEJ Cancer Receiving Maintenance Trastuzumab-Based Therapy (ESMO 2026) - No abstract available

Biomarker • Clinical • Metastases • Gastric Cancer • Oncology • HER-2

FLOT plus trastuzumab in metastatic HER2-positive oesophageal and gastro-oesophageal junction adenocarcinoma: a real world cohort from a tertiary centre in India (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Gastroesophageal Junction Adenocarcinoma • Oncology • HER-2

Post-Mastectomy Radiotherapy in pT1-2N1 HER2-Enriched Breast Cancer: Reassessing Its Role in the Anti-HER2 Era (ASTRO 2026) - "In the subset receiving Herceptin-based anti-HER2 therapy (n= 367), the 6-year LRRFS, BCRFS, and BCSS rates were 97.2%, 94.4%, and 97.7%, respectively... This study demonstrates that LRR rates are low in pT1-2N1 HER2-enriched breast cancer patients treated with mastectomy and contemporary systemic treatment. The addition of PMRT may not provide a significant survival benefit, suggesting a potential for treatment de-escalation in this specific patient population."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • ER • PGR

Comparative Efficacy of Trastuzumab Monotherapy Versus Dual HER2 Blockade as Neoadjuvant Therapy in HER2-Positive Breast Cancer in a Resource-Limited Setting (ESMO 2026) - No abstract available

Clinical • Monotherapy • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

The Effect of Trastuzumab on Cardiac Function in The Treatment of Libyan Human Epidermal Receptor-2 Positive Breast Cancer Patients. (ESMO 2026) - No abstract available

Clinical • Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

De-escalation of pertuzumab in node-negative HER2+ early breast cancer patients treated with neoadjuvant chemotherapy and trastuzumab (ESMO 2026) - No abstract available

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Comparing Trastuzumab and/or Lapatinib-Based Neoadjuvant Regimens in HER2-positive breast cancer: A Meta-Analysis Stratified by Chemotherapy Backbone (ESMO 2026) - No abstract available

Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Trastuzumab-induced cardiotoxicity in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials (ESMO 2026) - No abstract available

Retrospective data • Review • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Multicenter, phase II study of eribulin, carboplatin, trastuzumab and pertuzumab as neoadjuvant therapy in HER2-positive early or locally advanced breast cancer (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Neoadjuvant Chemotherapy plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer: A Prospective, Single-arm, Multi-center Study (NEOTORCH-BREAST05) (ESMO 2026) - No abstract available

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2